Company: KROS
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0001104659-25-037982
Chunk: 46

Company: Keros Therapeutics, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 46
---
 Senior Director, Program Management from 2008 to 2010, Vice President, Program Management from 2010 to 2013 and Senior Vice President, Program Management and Operations from 2013 to May 2018. Prior to Acceleron Pharma Inc., Mr. Rovaldi worked at Idenix Pharmaceuticals, Inc. from 2004 to 2007 and at Cubist Pharmaceuticals, Inc. from 2000 to 2004. He has over 20 years of program and portfolio management experience developing biologics and small molecules from the pre-investigational new drug application stage to marketing authorization. Mr. Rovaldi received a B.S. and an M.Sc. degree, each in Microbiology, from the University of New Hampshire.

29

TABLE OF CONTENTS COMPENSATION DISCUSSION AND ANALYSIS This Compensation Discussion and Analysis provides an overview of the material components of our executive compensation program for the fiscal year ended December 31, 2024, for our “named executive officers” who are listed below. This discussion and analysis summarizes our executive compensation philosophy, the overall objectives of our executive compensation program, how each element of our executive compensation program is designed to satisfy those objectives, the policies underlying our executive compensation program and the compensation awarded to our named executive officers for 2024. The following discussion and analysis should be read together with the compensation tables and related disclosures. Named Executive Officers Our named executive officers for the fiscal year ended December 31, 2024, are our principal executive officer, principal financial officer and our two other most highly compensated executive officers who were serving as executive officers as of December 31, 2024, as reflected below. We have no other executive officers who were serving as of December 31, 2024. Because Dr. Cooper served as an executive officer during 2024 prior to his resignation, he is also a named executive officer for 2024. • Jasbir Seehra, Ph.D., Chief Executive Officer and Chair (1) ; • Keith Regnante, Chief Financial Officer; • Yung Chyung, M.D., Chief Medical Officer (2) ; and • Simon Cooper, M.B.B.S., Former Chief Medical Officer (3) ; and • Christopher Rovaldi, President and Chief Operating Officer (4) . (1) Dr. Seehra was appointed to serve as our Chair, effective July 1, 2024. (2) Dr. Chyung was appointed to serve as our Chief Medical